1. Home
  2. PK vs HROW Comparison

PK vs HROW Comparison

Compare PK & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Park Hotels & Resorts Inc.

PK

Park Hotels & Resorts Inc.

HOLD

Current Price

$11.10

Market Cap

2.1B

Sector

Real Estate

ML Signal

HOLD

Logo Harrow Inc.

HROW

Harrow Inc.

HOLD

Current Price

$40.86

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PK
HROW
Founded
1946
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
1.7B
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
PK
HROW
Price
$11.10
$40.86
Analyst Decision
Hold
Strong Buy
Analyst Count
10
8
Target Price
$11.10
$69.86
AVG Volume (30 Days)
3.4M
459.6K
Earning Date
04-30-2026
05-07-2026
Dividend Yield
8.82%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,791,000,000.00
N/A
Revenue This Year
$2.48
$31.79
Revenue Next Year
$2.72
$49.04
P/E Ratio
N/A
N/A
Revenue Growth
2.35
N/A
52 Week Low
$9.51
$21.18
52 Week High
$12.39
$54.98

Technical Indicators

Market Signals
Indicator
PK
HROW
Relative Strength Index (RSI) 55.46 61.50
Support Level $10.07 $40.61
Resistance Level $11.77 $41.49
Average True Range (ATR) 0.31 1.53
MACD 0.10 0.95
Stochastic Oscillator 68.63 93.68

Price Performance

Historical Comparison
PK
HROW

About PK Park Hotels & Resorts Inc.

Park Hotels & Resorts owns upper-upscale and luxury hotels, with 21,042 rooms across 33 hotels in the United States. Park also has interests through joint ventures in another 1,712 rooms in two US hotels. Park was spun out of Hilton Worldwide Holdings at the start of 2017, so most of its hotels are still under the Hilton brand. The company has sold all its international hotels and many of its lower-quality US hotels to focus on high-quality assets in domestic gateway markets.

About HROW Harrow Inc.

Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.

Share on Social Networks: